Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Perqdisc Traditionele haalbaarheidsproef.

4 november 2026 bijgewerkt door: Spinal Stabilization Technologies

Een traditionele multi-center traditionele haalbaarheidstudie van het Perqdisc-kunstmatige implantaat bij de behandeling van discogene rugpijn op één niveau.

This is a traditional feasibility study (TFS) study to evaluate the safety and effectiveness of the PerQdisc. The study is prospective, multicenter, and open label.

After a screening period, qualified participants will be enrolled and treated with the PerQdisc. Patients will not be blinded to their treatment. Participants will then complete the safety follow-up period.

Studie Overzicht

Toestand

Werving

Interventie / Behandeling

Gedetailleerde beschrijving

The proposed investigation is a multicenter, prospective, traditional feasibility study of the PerQdisc. A minimum of N=5 subjects will be enrolled. Subjects will be enrolled in approximately 2 sites. Data analyses including all enrolled subjects meeting specific criteria will be submitted to the FDA to support a pivotal trial and used in trial planning. This study will evaluate the safety and effectiveness of the PerQdisc device in the treatment of single level discogenic back pain caused by degenerative disc disease (DDD) (L1 to L5).

Studietype

Ingrijpend

Inschrijving (Geschat)

5

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Arizona
      • Glendale, Arizona, Verenigde Staten, 85308
        • Ingetrokken
        • Hope Research Institute
      • Phoenix, Arizona, Verenigde Staten, 85032
        • Ingetrokken
        • HOPE Research Institute
      • Phoenix, Arizona, Verenigde Staten, 85023
      • Scottsdale, Arizona, Verenigde Staten, 85251
        • Werving
        • HonorHealth Research & Innovation Institute
        • Contact:
        • Hoofdonderzoeker:
          • Luis Tumialan, MD
    • Florida
      • Miami, Florida, Verenigde Staten, 33136
        • Werving
        • University of Miami
        • Hoofdonderzoeker:
          • Michael Wang, MD
        • Contact:
    • Idaho
      • Coeur d'Alene, Idaho, Verenigde Staten, 83854
        • Werving
        • Axis Spine Center
        • Hoofdonderzoeker:
          • Roland Kent, MD
        • Contact:
    • Indiana
      • Carmel, Indiana, Verenigde Staten, 46032
        • Werving
        • Indiana Spine Group
        • Contact:
        • Hoofdonderzoeker:
          • Paul Kraemer, MD
    • Louisiana
      • Shreveport, Louisiana, Verenigde Staten, 71101
        • Werving
        • Spine Institute of Louisiana
        • Contact:
        • Hoofdonderzoeker:
          • Pierce Nunley, MD
    • Oklahoma
      • Oklahoma City, Oklahoma, Verenigde Staten, 73159
        • Ingetrokken
        • SonoSpine

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

22 jaar tot 70 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Skeletally mature male or female subjects aged 22-70 (inclusive).
  2. Subject has a primary diagnosis of single level discogenic back pain caused by degenerative disc disease (L1 to L5) identified via MRI.
  3. Subject has an intact annulus (as determined by MRI) and endplates (as determined by MRI and X-ray) at the level to be treated.
  4. Subject must have failed to respond to a minimum of 6 months of conservative treatment for their back pain (e.g., physical therapy, medications, injections, ablations, lifestyle changes, etc.).
  5. Subject has a low back pain VAS ≥40 mm (4 cm).
  6. Subject has adequate disc height (≥6mm measured at the center of the disc) at the level to be treated. [As measured by the investigator]
  7. Subject is psychosocially, mentally and physically able and willing to fully comply with this protocol including adhering to follow-up schedule and requirements and filling out forms.
  8. Subject has read and understands the IRB approved informed consent document prior to signing and dating the document and before the initiation of any study-related procedures
  9. Subject is appropriate candidate for the PerQdisc surgical approach [as defined in the surgical technique guide].

Exclusion Criteria:

  1. Subject has symptomatic degenerative disc disease at more than one lumbar level

  2. Subject has had a prior spinal fusion in the lumbar or thoracic intervertebral spaces.

  3. Subject has had a prior SI-joint fusion.

  4. Subject has a spinal cord stimulator.

  5. Subject has had any prior lumbar spine surgery (instrumented or non-instrumented)

  6. Subject has a significant disc herniation at the level to be treated. Significant is defined as a large, extruded herniation that creates a risk for expulsion.

  7. Subject has congenital moderate or severe spinal stenosis or epidural lipomatosis.

  8. Subject has spondylolisthesis (antero- or retrolisthesis) in static X-ray ≥3 mm [measured via neutral lateral x-ray]

  9. Subject has ≥4 mm dynamic spondylolisthesis [measured via flexion/extension x-rays]

  10. Subject has > 20 degree range of motion at the index level [measured via flexion/extension x-rays]

  11. Subject has a history of any invasive malignancy (except non-melanoma skin cancer) unless treated with curative intent and there have been no clinical signs or symptoms of malignancy for at least 5 years (in particular, spinal tumors).

  12. Subject has an active systemic infection or infection at the operative site.

  13. Subject has evidence of symptomatic facet joint degeneration or disease where the investigator feels the facet is a major contributor to the subject's pain as diagnosed by injection and/or imaging.

  14. Subject has a known allergy to silicone or barium sulfate.

  15. Subject has been diagnosed with fibromyalgia, hepatitis, rheumatoid arthritis, lupus erythematosus, AIDs, ARC, HIV, or an autoimmune disease that affects the musculoskeletal system.

  16. Subject has been diagnosed with Paget's disease, osteomalacia or any other metabolic bone disease.

  17. Subject has current or recent history (defined ≤ 1 year prior to screening) of substance abuse (alcoholism and/or narcotic addiction) using standard medical definitions of DSM-5

  18. Subject has morbid obesity defined as a body mass index (BMI) > 40.

  19. Subject participated in an investigational drug or another medical device study within the last 30 days prior to surgery.

  20. Subject has Osteoporosis, defined as a T-score ≤ -2.5.

    1. An existing DEXA is allowed if completed within 6 months of subject surgery.
    2. For all subjects without an existing DEXA, the SCORE/MORES will be utilized to screen if a DEXA scan is indicated. If SCORE/MORES value ≥ 6, then a DEXA scan is required.
  21. Female subjects who are pregnant or are trying to become pregnant during the course of the trial.

  22. Subject has diabetes mellitus (Type 1 or 2) requiring daily insulin management.

  23. Subject belongs to a vulnerable population or has a condition such that his/her ability to provide informed consent, comply with follow-up requirements, or provide self-assessments is compromised (e.g. developmentally disabled, prisoner, chronic alcohol/ substance abuser)

  24. Subject is currently receiving worker's compensation or is involved in any litigation for medical negligence, trauma, or worker's compensation.

  25. Subject has lumbar scoliosis > 10 degrees at index level.

  26. Subject has a large, rectangular or irregularly shaped Schmorl's node with an associated active inflammatory process (Modic I changes).

  27. Subject has motion of < 3 degrees on pre-operative lateral flexion/extension radiographs at index level.

  28. Subject has opioid medication usage > 60 MME (morphine milligram equivalent)/day or change in opioid prescription within 60 days of surgery.

  29. Subject has a preoperative VAS right or left leg pain score > the preoperative VAS Back score.

  30. Subject has a history of vertebral fractures in the lumbar spine.

  31. Subject has evidence of severe compression of cauda equina.

  32. Subject is on chronic anticoagulation therapy due to a bleeding disorder and is unable to safely stop anticoagulants or has taken anticoagulants within 3 days prior to procedure.

  33. Subject has low back pain (LBP) of non-spinal or unknown etiology.

  34. Subject is unable to undergo X-ray, MRI, or other radiographic assessments, including discography.

  35. Subject has a degenerative muscular or neurological condition that would interfere with evaluation of outcomes, including but not limited to spinal disease (not at index level), Parkinson's disease, amyotrophic lateral sclerosis (ALS), or multiple sclerosis.

  36. Subject has, in the opinion of the investigator, a behavioral, cognitive, social or medical problem that may interfere with the assessment of the safety or effectiveness of the device.

  37. In the opinion of the investigator the subject has a major psychiatric disorder that may interfere with the assessment of the safety or effectiveness of the device.

  38. Subject has myelopathy.

  39. Subject has primarily leg pain with associated nerve root compression, in the opinion of the investigator.

  40. Subject has an annular defect greater than 6mm that extends from the interior of the disc to the outer margin of the annulus as evaluated on MRI.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: PerQdisc

The PerQdisc device is the first in a new category of contained in-situ filled and then cured lumbar spinal implant. The PerQdisc is intended to replace the nucleus pulposus in a single lumbar disc level, preserve motion and alleviate pain. The PerQdisc is a silicone membrane (barrier membrane) configured to be filled with a room temperature vulcanizing silicone (RTVS) that will cure within minutes, resulting in a final shape that conforms to the nucleus space created by the surgical removal of the diseased or damaged nucleus pulposus.

PerQdisc Artificial Implant

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Clinical Composite Success
Tijdsspanne: 6 Months

Clinical composite success is defined as improvement in pain and absence of qualified safety events.

6 Months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
ODI
Tijdsspanne: 6 Months

ODI 15-point responder at Month 6

6 Months
VAS Back
Tijdsspanne: 6 Months

VAS Back pain 20mm responder at Month 6

6 Months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

10 januari 2025

Primaire voltooiing (Geschat)

30 september 2027

Studie voltooiing (Geschat)

31 maart 2030

Studieregistratiedata

Eerst ingediend

28 februari 2025

Eerst ingediend dat voldeed aan de QC-criteria

28 februari 2025

Eerst geplaatst (Werkelijk)

6 maart 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

9 november 2026

Laatste update ingediend die voldeed aan QC-criteria

4 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • DISCPAIN1 TFS

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Ja

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren